Modality
Vaccine
MOA
ALKi
Target
C5
Pathway
Neuroinflam
Ewing Sarcoma
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Apr 2030
Phase 1Current
NCT06833699
1,223 pts·Ewing Sarcoma
2023-12→2030-04·Not yet recruiting
NCT07111341
1,339 pts·Ewing Sarcoma
2018-01→2026-08·Active
2,562 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-074mo awayInterim· Ewing Sarcoma
2030-04-014.0y awayInterim· Ewing Sarcoma
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Active
P1
Not yet…
Catalysts
Interim
2026-08-07 · 4mo away
Ewing Sarcoma
Interim
2030-04-01 · 4.0y away
Ewing Sarcoma
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06833699 | Phase 1 | Ewing Sarcoma | Not yet recr... | 1223 | CfB |
| NCT07111341 | Phase 1 | Ewing Sarcoma | Active | 1339 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |